Jansitin

Sitagliptin, the active ingredient in Jansitin, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, where it enhances glucose‑dependent insulin secretion and reduces post‑prandial glucose excursions, supporting overall glycemic control.

GNH USA supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU standards and ensures timely delivery to diverse markets.

Sitagliptin is used in the management of type 2 diabetes, acting on the incretin pathway to improve glycemic control. - Type 2 diabetes mellitus: improves blood glucose levels when combined with diet and exercise. - Adjunct therapy for type 2 diabetes: enhances insulin secretion in patients inadequately controlled on metformin. - Combination therapy with other antidiabetic agents: provides additional HbA1c reduction alongside sulfonylureas or insulin.

Sitagliptin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in some patients. - Headache: transient head discomfort reported during treatment. - Nasopharyngitis: upper respiratory tract infection symptoms such as sore throat or runny nose.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent.

When prescribing sitagliptin, clinicians should consider several safety considerations to minimize risk. - Renal function: assess baseline kidney function and adjust use in moderate to severe impairment. - Hypoglycemia risk: monitor blood glucose closely if combined with insulin or sulfonylureas. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Elderly patients: consider initiating at a lower dose due to potential decreased clearance. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin: concurrent use may increase risk of hypoglycemia. - Sulfonylureas: combined therapy can potentiate low blood glucose episodes. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function as changes may affect sitagliptin clearance. - Rifampin: may reduce sitagliptin exposure, potentially diminishing glycemic effect.